gdc
FDA Approvals, News & UpdatesMultiple Myeloma

FDA Approved Pepaxto for Relapsed or Refractory Multiple Myeloma

Pepaxto is a novel therapy that has shown good results in multiple myeloma that does not respond to other therapies, according to myeloma expert Paul G. Richardson, MD, of Dana-Farber Cancer Institute.
April 2021 Vol 7 No 2

In February 2021, the FDA approved Pepaxto (melphalan flufenamide; from Oncopeptides AB), for the treatment (in combination with dexamethasone) of adults with relapsed or refractory multiple myeloma who had received 4 or more lines of therapy and whose disease has not responded to 3 types of drugs, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody. Pepaxto is the first peptide–drug conjugate approved for multiple myeloma.

“Research has shown melphalan flufenamide to be a novel and innovative therapeutic option, which is active in refractory disease and has manageable toxicity, with the convenience of being administered by infusion once a month,” said Paul G. Richardson, MD, Director of Clinical Research at the Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute. “Based on our findings, melphalan flufenamide is an important addition to the treatment armamentarium, with the potential to meaningfully improve outcomes in an area of important unmet medical need.”

This approval was based on results for 97 patients with relapsed or refractory multiple myeloma who previously received 4 or more therapies. The patients received intravenous Pepaxto on day 1 and oral dexamethasone on days 1, 8, 15, and 22 of every 28-day cycle, until disease progression or until unacceptable side effects.

The overall response rate was 23.7% and the average duration of response was 4.2 months.

The most common side effects with melphalan flufenamide were fatigue, nausea, diarrhea, fever, and respiratory tract infection.

Share this:

Recommended For You
Patient StoriesMultiple Myeloma
Living My Life While Dealing with Multiple Myeloma
By Thomas Goode
Thomas Goode always worked out; when he felt an excruciating pain on his left side one day working out, he knew something was wrong and visited a surgeon. After terrible back pain months later and another x-ray and MRI, he was diagnosed with multiple myeloma.
Letters to the EditorMultiple Myeloma
Thank You CONQUER Magazine for a Great Article
By Sally K. Koski, PhD, RN
Sally K. Koski, PhD, RN, expresses her gratitude to CONQUER magazine for the very informative article, “Multiple Myeloma: Navigating the First 90 Days,” which was featured in the April 2022 issue.
Multiple MyelomaPatient Stories
Targeting a Better Future for Patients with Multiple Myeloma
By Christopher Greklek
Christopher Greklek competed in Ironman races and was shocked when he was diagnosed with multiple myeloma. He describes being in and out of remission repeatedly, citing a program seeking to improve patient options.
Last modified: March 10, 2022

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country
Gender
Race or Ethnicity
Profession or Role
Primary Interest